Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-01-06
2010-10-12
Reddig, Peter J (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007230, C530S387100, C530S387700, C530S388100, C530S389100, C530S391100
Reexamination Certificate
active
07811772
ABSTRACT:
The present invention provides a protein-based biomarker, ApoA-II isoform, that is useful in determining prostate cancer status in a patient. In particular, the biomarker of this invention is useful to classify a biological sample as prostate cancer or non-prostate cancer. The ability of ApoA-II to detect disease in patients with a normal prostate-specific antigen (PSA) makes the biomarker of this invention useful in identifying indolent disease. The biomarker can be detected by SELDI mass spectrometry, HPLC, PAGE and Western blotting.
REFERENCES:
patent: 5242828 (1993-09-01), Bergstrom et al.
patent: 5500347 (1996-03-01), Moll et al.
patent: 5512657 (1996-04-01), Van Aken et al.
patent: 5719060 (1998-02-01), Hutchens et al.
patent: 5894063 (1999-04-01), Hutchens et al.
patent: 6020208 (2000-02-01), Hutchens et al.
patent: 6124137 (2000-09-01), Hutchens et al.
patent: 6225047 (2001-05-01), Hutchens et al.
patent: 6283761 (2001-09-01), Joao
patent: 6329209 (2001-12-01), Wagner et al.
patent: 6555813 (2003-04-01), Beecher et al.
patent: 6579719 (2003-06-01), Hutchens et al.
patent: 2002/0138208 (2002-09-01), Paulse et al.
patent: 2002/0193950 (2002-12-01), Gavin et al.
patent: 2003/0004402 (2003-01-01), Hitt et al.
patent: 2003/0032043 (2003-02-01), Pohl et al.
patent: 2003/0055615 (2003-03-01), Zhang et al.
patent: 2003/0073096 (2003-04-01), Bao et al.
patent: 2003/0105000 (2003-06-01), Pero et al.
patent: 2003/0119033 (2003-06-01), Mikolajczyk et al.
patent: 2003/0207462 (2003-11-01), Kitagawa
patent: 2003/0218130 (2003-11-01), Boschetti et al.
patent: 2003/0224399 (2003-12-01), Reed et al.
patent: 2004/0018519 (2004-01-01), Wright , Jr.
patent: 1300683 (2003-04-01), None
patent: WO-9324834 (1993-12-01), None
patent: WO-9859360 (1998-12-01), None
patent: WO-9859362 (1998-12-01), None
patent: WO-9951773 (1999-10-01), None
patent: WO-0019208 (2000-04-01), None
patent: WO-0029987 (2000-05-01), None
patent: WO-0056934 (2000-09-01), None
patent: WO-0066265 (2000-11-01), None
patent: WO-0131580 (2001-05-01), None
patent: WO-0136977 (2001-05-01), None
patent: WO-0171360 (2001-09-01), None
patent: WO-03031031 (2003-04-01), None
patent: WO-03040700 (2003-05-01), None
patent: WO-03091695 (2003-11-01), None
patent: WO-2004030511 (2004-04-01), None
Boyd (The Basic Science of Oncology, 1992, McGraw-Hill, Inc., p. 379).
Tockman et al (Cancer Res., 1992, 52:2711s-2718s).
Pritzker (Clinical Chemistry, 2002, 48:1147-1150).
The National Cancer Institute (Dictionary of Cancer Terms, stage, www.cancer.gov. Dec. 2009).
Rudikoff et al. (PNAS, USA, 1982, 79: 1979-1983).
Coleman et al. (Research in Immunology, 1994; 145(1): 33-36).
Abaza et al. (Journal of Protein Chemistry, vol. 11, No. 5, 1992, pp. 433-444).
Gussow et al. (1991, Methods in Enzymology 203:99-121).
MacCallum et al. (J. Mol. Biol. (1996) 262, 732-745).
Malik et al. (Proc. Amer. Assoc. Can. Res. Mar. 27-31, 2004 45:843).
Usui et al. (Clinical Chimica Acta 317: 2002 133-143).
Sambrook et al. (Molecular cloning: A Laboratory Manual, 2nd ed. Cold Spring Harbor Laboratory Press 1989, pp. 18.60-18.61).
European Search Report, dated Jan. 30, 2009, EPO App 06717624.8.
PCT International Search Report for Application No. PCT/US06/00450 dated Oct. 5, 2006.
Aspinall, et al., J Urol, 154:622-628 (1995).
Ball, et al., Bioinformatics, 18:395-404 (2002).
Banez, et al., J Urol, 170:442-446 (2003).
Banks, et al., “Soluble forms of the adhesion molecule E-cadherin in urine,” J Clin Pathol, vol. 48, pp. 179-180 (1995).
Barnathan, et al., “Immunohistochemical Localization of Defensin in Human Coronary Vessels,” American Journal of Pathology, vol. 150, No. 3, pp. 1009-1020, Mar. 3, 1997.
Bisgaier and Glickman, Annu Rev Physiol, 45:625-636 (1983).
Blanco-Vaca, et al., J Lipid Res. 33:1785-1796 (1992).
Brewer, et al., Proc Natl Acad Sci USA, 69:1304-1308 (1972).
Carr, et al., “Integration of Mass Spectrometry in Analytical Biotechnology,” Anal Chem, vol. 63, pp. 2802-2824 (1991).
Carr, S. and Roland, S., “Overview of Peptide and Protein Analysis by Mass Spectrometry,” Current Protocols in Molecular Biology, Supplement 38, pp. 10.21.1-10.21.27 (1997).
Carter, N. Engl J Med., 350:2292-2294 (2004).
Celis, J., “A comprehensive protein resource for the study of bladder cancer: http://biobase.dk/cgi-bin/celis,” Electrophoresis, vol. 20, pp. 300-309 (1999).
De Marzo, et al., Am J Pathol, 153:911-919 (1998).
Deterding, et al., Eletrophoresis, 23:2296-2305 (2002).
Dhom, J. Cancer Res Clin Oncol, 106:210-218 (1983).
Diaz, et al., Urology, 53:931-938 (1999).
Edelstein, et al., J Biol Chem, 257:7189-7195 (1982).
Freeman and Solomon, J Cell Biochem, 91:54-69 (2004).
Gambert, Geriatrics, 56:22-26 (2001).
Garnick, Annals of Internal Medicine, 118:803-818 (1993).
Garnick, Scientific American, 270:72-81 (1994).
Golijanin, et al., Detection of Bladder Tumors by Immunostaining of the Lewis X Antigen in Cells from Voided Urine, Adult Urology, vol. 46, No. 2, pp. 173-177 (1995).
Gordon, et al., J Biol Chem, 258:14054-14059 (1983).
Grizzle, et al., In: M. Hanausek, Walasze, Z. (ed.), John Walker's Methods in Molecular Medicine—Tumor Marker Protocols, pp. 161-179: Humana Press, Inc., Totowa, NJ (1998).
Grizzle, et al., In: M. Hanausek, Walasze, Z. (ed.), John Walker's Methods in Molecular Medicine—Turmor Marker Protocols, pp. 143-160: Humana Press, Inc., Totowa, NJ (1998).
Halachmi, et al., “Urine cytology, tumour markers and bladder cancer,” British Journal of Urology, vol. 83, pp. 647-654 (1998).
Hansson, et al., Immunotechnology, (3-4):237-252 (1999).
Jahn, et al., FEBS Lett, 131:366-368 (1981).
Jaroff, Time (Apr. 1, 1996).
Karp, et al., Cancer Res., 56:5547-5556 (1996).
Klein, et al., “Expression of Cytokeratin 20 in Urinary Cytology of Patients with Bladder Carcinoma,” American Cancer Society, pp. 349-354 (1998).
Koopman, et al., Clin Cancer Res, 10:860-868 (2004).
Kozak, et al., Proc Natl Acad Sci USA, 100:12343-12348 (2003).
Kuwata, H., “Bactericidal Domain of Lactoferrin: Detection, Quantitation, and Characterization of Lactoferrincin in Serum by SELDI Affinity Mass Spectrometry,” Biochemical and Biophysical Research Communications, vol. 245, pp. 764-773 (1998).
Lackner, et al., J. Biol Chem, 260:703-705 (1985).
Lehrer, Br J Cancer, 78:1398 (1998).
Liu, B, et al., “Detection of Onco-Fetal Bladder Antigen in Urine of Patients with Transitional Cell Carcinoma,” The Journal of Urology, vol. 137, pp. 1258-1261, Jun. 1987.
Lokeshwar, et al., “Tumor-associated Hyaluronic Acid: A New Sensitive and Specific Urine Marker for Bladder Cancer,” Cancer Research, vol. 57, pp. 773-777, Feb. 15, 1997.
Lopez-Ottin, et al., Nature Reviews, 3:509-519 (2002).
Malik, et al., “Serum Levels of an Isoform of Apolipoprotein A-II as a Potential Marker for Prostate Cander,” Clin. Cancer Res., vol. 11, No. 3, pp. 1073-1085, Feb. 1, 2005.
McCormack, et al., Urology, 45:729-744 (1995).
McDavid, et al., Public Health Rep, 119:174-186 (2004).
Merchant, et al., Electrophoresis, 21:1164-1167 (2000).
Mizukawa, N., et al., “Presence of Defensin in Epithelial Langerhans Cells Adjacent to Oral Carcinomas and Precancerous Lesions,” Anticancer Research, vol. 19, pp. 2969-2972 (1999).
Mizukawa, N., et al., “Immunohistochemical Staining of Human α-Defensin-1 (HNP-1), in the Submandibular Glands of Patients with Oral Carcinomas,” Anticancer Research, vol. 20, pp. 1125-1128 (2000).
Myers, et al., J Urol, 165:1027-1032 (2001).
Niederkofler, et al., J Lipid Res, 44:630-639 (2003).
Nord, et al., Eur J Biochem, 15:4269-4277 (2001).
Paweletz, D., “Rapid Protein Display Profiling of Cancer Progression Directly from Human Tissue Using a Protein Biochip,” Drug Development Research, vol. 49, pp. 34-42 (2000).
Pham, et al., “Tumor-derived Hyaluronidase: A Diagnostic Urine Marker for High-Grade Bladder Cancer,” Cancer Research, vol. 57, pp. 778-783, Feb. 15, 1997.
Platz, et al., J Cell Biochem, 91:55
Malik Gunjan
Semmes O. John
Ward Michael D.
Eastern Virginia Medical School
Reddig Peter J
Wilmer Cutler Pickering Hale and Dorr LLP
LandOfFree
Apolipoprotein A-II isoform as a biomarker for prostate cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Apolipoprotein A-II isoform as a biomarker for prostate cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Apolipoprotein A-II isoform as a biomarker for prostate cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4181030